The ink on Kyle Bradish's contract was barely dry before things started going wrong.
On July 18, 2026, the Orioles announced a five-year deal covering 2027-31 for Bradish, which ESPN's Jeff Passan reported at $90 million with no option years. It bought out his final two arbitration years and his first three trips through free agency, making him the highest-paid pitcher in franchise history. CBS Sports called it the third-largest guarantee ever handed to a pitcher two years away from free agency. Owner David Rubenstein put a bow on it: "Keeping players of Kyle's caliber in an Orioles uniform is an important part of our long-term vision."
Then Bradish fell apart. After beating Boston on July 22, he went 0-5 with a 5.83 ERA. His final outing came Saturday, on his 30th birthday, against Toronto: five runs and eight hits in three innings, his ninth straight winless start. The next day the Orioles put him on the 15-day injured list with lower abdominal discomfort. His season was effectively over. Manager Craig Albernaz said Bradish had been dealing with a lower abdominal strain for a while. Days later came the diagnosis: a sports hernia. Surgery is on the table, and if the Orioles reach the postseason, he's likely unavailable.
His season closed at 7-14 with a 4.12 ERA over 155 innings in 29 starts, his most innings since 2023. The last nine starts, a 5.83 ERA, were a slow-motion breakdown.
Nobody has connected the sports hernia to his 2024 Tommy John surgery. They're different injuries in different parts of the body. This is a story about judgment, not an elbow betraying him.
Look at the timeline Baltimore worked with. Bradish had surgery in June 2024. He returned on August 26, 2025, and threw six strong starts. When Baltimore committed $90 million to his future, he was 29 years old, 6-9 with a 3.61 ERA in 19 starts, and in the middle of his first full season back from that surgery, not after it. He hadn't completed a single healthy, durable, wire-to-wire season since the surgery, and the Orioles paid him as if he had.
That's the gamble. You can love the pedigree, and the pedigree is real: fourth in AL Cy Young voting in 2023 with a 2.83 ERA over 30 starts. That version of Bradish is a legitimate front-of-rotation arm and worth every dollar. But the whole reason you wait a full season on a recovering pitcher is to see whether the body holds up across a real workload. Baltimore skipped the audition and wrote the check. Then the body didn't hold up.
This fits a pattern in Baltimore. The Bradish deal was the third long-term extension in under a year, following catcher Samuel Basallo (eight years, $67 million) and righty Shane Baz (five years, $68 million). Locking up your young core early is a defensible approach. Doing it with a pitcher who hasn't proven he can survive a full season is where that approach meets its test.
There's a fair counterpoint here. Not a dollar of the new deal is due until 2027. Bradish gets a full offseason, and a possible surgery-and-recovery window, before he's asked to throw a single inning under the contract. The Baltimore Banner's beat reporting framed 2026 as a strong return from elbow surgery overall, with Bradish well positioned to come back as a high-end starter. That's reasonable. The structure of the deal gives Baltimore cover it might badly need.
But cover isn't vindication. The point of extending a pitcher before he reaches free agency is to buy certainty at a discount. The Orioles bought the opposite. They now enter an offseason not knowing whether their franchise-record pitcher needs surgery, how his body responds, or what he looks like in the spring. If he bounces back, this becomes a footnote and a bargain. If he doesn't, it's a five-year reminder that you don't hand out generational money to a pitcher who hasn't yet answered the one question the money is supposed to answer.
As of mid-September, when Bradish went on the IL, Baltimore sat three games back in the wild-card race with 13 games left, and the standings have shifted since. Wherever the Orioles finish, they'll do it without the pitcher they just bet the rotation on. Every team eyeing an early extension for an arm coming back from surgery should study this one. Wait for the full season. Make him earn it. Baltimore didn't, and right now that call looks expensive.
